-
Mashup Score: 0Krish Patel, MD, Talks Gilteritinib, Other Novel Frontline Therapies in DLBCL | Blood Cancers Today - 11 day(s) ago
“Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
Extrachromosomal DNA was highly expressed in 18 DLBCL cell lines, especially relapsed or refractory cases, and may function as a powerful prognostic indicator.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 0
The phase 3 STARGLO trial met its primary end point, improving overall survival in patients with relapsed/refractory diffuse large B-cell lymphoma with glofitamab and chemotherapy vs rituximab and chemotherapy.
Source: www.targetedonc.comCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 10Krish Patel, MD, Talks Gilteritinib, Other Novel Frontline Therapies in DLBCL | Blood Cancers Today - 1 month(s) ago
“Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 8Krish Patel, MD, Talks Gilteritinib, Other Novel Frontline Therapies in DLBCL | Blood Cancers Today - 1 month(s) ago
“Having something that could cure patients after failing CAR-T is huge,” host Dr. Chadi Nabhan said during the episode.
Source: bloodcancerstoday.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
-
Mashup Score: 4
An abstract is unavailable.
Source: journals.lww.comCategories: General Medicine News, Onc News and JournalsTweet-
“We determined that two common and easily measured blood tests can identify in advance which [DLBCL] patients are at high risk for poor outcomes after treatment with CD19-targeted CAR-T cells,” said Marco Davila, MD, PhD. Keep reading: https://t.co/7pT5U3vaDl @MarcoLDavila #DLBCL https://t.co/sGYZjNwLYK
-
🚨 Out now! The latest "HemOnc Pulse" episode with @chadinabhan featuring @KrishPatelMD, of @ProvSwedCancRes. 🎙️ They discuss novel frontline therapies in the lymphoma space, including the bispecific antibody gilteritinib. #DLBCL 🎧 Listen here! https://t.co/AyJlXtikzZ https://t.co/ECgfNlyaYc